[go: up one dir, main page]

UY32486A - Tratamiento del cáncer de páncreas - Google Patents

Tratamiento del cáncer de páncreas

Info

Publication number
UY32486A
UY32486A UY0001032486A UY32486A UY32486A UY 32486 A UY32486 A UY 32486A UY 0001032486 A UY0001032486 A UY 0001032486A UY 32486 A UY32486 A UY 32486A UY 32486 A UY32486 A UY 32486A
Authority
UY
Uruguay
Prior art keywords
cancer
treatment
iodophenylamino
fluoro
pharmaceutically acceptable
Prior art date
Application number
UY0001032486A
Other languages
English (en)
Inventor
Md Mark S Chapman
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42129806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of UY32486A publication Critical patent/UY32486A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con el campo de la oncología y con el uso de la (S) -N-(3,4-difluoro-2-(2- fluoro-4-iodofenilaminoi)-6-metoxifenil)-1-(2,3-dihidroxi-propil)ciclopropano-1-sulfonamida o de una sal farmacéuticamente aceptable de ésta, o de la N-(4-(2-fluoro-4-iodofenilamino)-1,5-dimetil-6-oxo-1,6-dihidropiridin-3-il)ciclopropanosulfonamida o de una forma polimórfica de ésta o de una sal farmacéuticamente aceptable de ésta, o de composiciones farmacéuticas que las comprenden, para la preparación de un medicamento para el tatamiento del cáncer de páncreas.
UY0001032486A 2009-03-11 2010-03-10 Tratamiento del cáncer de páncreas UY32486A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15939709P 2009-03-11 2009-03-11

Publications (1)

Publication Number Publication Date
UY32486A true UY32486A (es) 2010-10-29

Family

ID=42129806

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032486A UY32486A (es) 2009-03-11 2010-03-10 Tratamiento del cáncer de páncreas

Country Status (20)

Country Link
US (1) US20120053211A1 (es)
EP (1) EP2405907A1 (es)
JP (1) JP2012520319A (es)
KR (1) KR20110128916A (es)
CN (1) CN102438609A (es)
AU (1) AU2010224108A1 (es)
BR (1) BRPI1009435A2 (es)
CA (1) CA2754891A1 (es)
CL (1) CL2011002234A1 (es)
CR (1) CR20110478A (es)
EA (1) EA201101305A1 (es)
IL (1) IL215037A0 (es)
MA (1) MA33109B1 (es)
MX (1) MX2011009494A (es)
SG (1) SG174271A1 (es)
SV (1) SV2011004017A (es)
TN (1) TN2011000456A1 (es)
TW (1) TW201100081A (es)
UY (1) UY32486A (es)
WO (1) WO2010105082A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121471A1 (es) 2009-11-04 2012-11-01 Novartis Ag Derivados de sulfonamida heterociclicos utiles como inhibidores de mek
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
KR101980809B1 (ko) * 2017-09-29 2019-05-21 대한민국 귀리껍질 추출물을 포함하는 췌장암의 예방 또는 치료용 약학적 조성물
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8005A (en) * 1851-04-01 He ne y bo o t
US9022A (en) * 1852-06-15 Organ
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2649122C (en) * 2006-04-18 2015-06-30 Ardea Biosciences, Inc. Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
KR20100092424A (ko) * 2007-07-30 2010-08-20 아디아 바이오사이언스즈 인크. 다형체를 포함하는, mek의 억제제로서의 n-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof

Also Published As

Publication number Publication date
IL215037A0 (en) 2011-11-30
CR20110478A (es) 2011-10-24
CA2754891A1 (en) 2010-09-16
EA201101305A1 (ru) 2012-04-30
AU2010224108A1 (en) 2011-09-22
MX2011009494A (es) 2011-10-11
MA33109B1 (fr) 2012-03-01
US20120053211A1 (en) 2012-03-01
KR20110128916A (ko) 2011-11-30
TW201100081A (en) 2011-01-01
CL2011002234A1 (es) 2012-01-27
CN102438609A (zh) 2012-05-02
SG174271A1 (en) 2011-10-28
WO2010105082A1 (en) 2010-09-16
EP2405907A1 (en) 2012-01-18
JP2012520319A (ja) 2012-09-06
BRPI1009435A2 (pt) 2016-03-01
SV2011004017A (es) 2012-01-06
TN2011000456A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CY1119177T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων
MX2018001193A (es) Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
UY37842A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
UY37843A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
BR112013028665A2 (pt) compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
UY37844A (es) Inhibidores de mcl-1 macrocíclicos y métodos de uso
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
CR20140086A (es) Tratamientos de combinación para hepatitis c
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
BR112014017780A8 (pt) Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
UY32486A (es) Tratamiento del cáncer de páncreas
UY36124A (es) Derivados de carboxamida
ECSP19019613A (es) Compuestos de aza–indazol para usar en lesiones de tendones y/o ligamentos
MX382765B (es) Tratamiento para la colangitis biliar primaria.
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
JOP20190049A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20190122